Geographic Atrophy Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | Apellis Pharma, Iveric bio., Belite Bio, NGM Biopharma

DelveInsight’s “Geographic Atrophy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Geographic Atrophy, historical and forecasted epidemiology as well as the Geographic Atrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Geographic Atrophy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Geographic Atrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Geographic Atrophy Market Insights

Some of the key facts of the Geographic Atrophy Market Report: 

• The Geographic Atrophy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In January 2024, Aviceda Therapeutics has released encouraging top-line results from the first part of a Phase II/III trial investigating its product AVD-104 in individuals with geographic atrophy (GA) linked to age-related macular degeneration (AMD). The study recorded favorable safety and efficacy outcomes three months post-administration of a single dose of AVD-104, an intravitreal glycan-coated nanoparticle. The Phase II SIGLEC trial is a two-part study conducted in the United States (NCT05839041), assessing the safety, pharmacokinetics, and effectiveness of intravitreal AVD-104.
• In February 2023, The US FDA approved the NDA for Zimura in geographic atrophy and granted priority review along with a Prescription Drug User Fee Act (PDUFA).
• In February 2023, The US Food and Drug Administration (FDA) gave approval to SYFOVRE (pegcetacoplan injection) for treating geographic atrophy secondary to age-related macular degeneration.
• In the year 2021, the total prevalent case of Geographic Atrophy was 3,056,205 cases in the 7MM. These cases are expected to grow with a significant CAGR in the study period 2019–2032
• In the 7MM, the total diagnosed cases of Geographic Atrophy were 2,822,853 cases in 2021. These cases are expected to grow with a significant CAGR in the study period 2019–2032
• Globally, more than 5 million people are affected by Geographic Atrophy. Also, as per the published study by GER group, the global prevalence of Geographic Atrophy is 0.66% in all ages
• As per National Institute for Health and Care Excellence (NICE) 2019, the prevalence rate of Geographic Atrophy in the United Kingdom was found to be between 1.3%-6.7%
• Key Geographic Atrophy Companies: Apellis Pharmaceuticals, Iveric bio., Belite Bio, NGM Biopharmaceuticals, Novartis, CellCure Neurosciences, and others
• Key Geographic Atrophy Therapies: Pegcetacoplan, Zimura, LBS-008, NGM621, PPY988/GT005, OpRegen, and others

Geographic Atrophy Overview

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD), a progressive eye condition affecting the macula, the central part of the retina responsible for sharp, central vision. In GA, there is a gradual loss of retinal pigment epithelial cells and photoreceptors, leading to the formation of distinct areas of retinal degeneration known as “geographic” lesions. 

Get a Free sample for the Geographic Atrophy Market Report:

https://www.delveinsight.com/report-store/geographic-atrophy-ga-market

Geographic Atrophy Market  

The dynamics of the Geographic Atrophy market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.  

Geographic Atrophy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Geographic Atrophy Epidemiology Segmentation:

The Geographic Atrophy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Geographic Atrophy
• Prevalent Cases of Geographic Atrophy by severity
• Gender-specific Prevalence of Geographic Atrophy
• Diagnosed Cases of Episodic and Chronic Geographic Atrophy

Download the report to understand which factors are driving Geographic Atrophy epidemiology trends @ Geographic Atrophy Epidemiological Insights

Geographic Atrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Geographic Atrophy market or expected to get launched during the study period. The analysis covers Geographic Atrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Geographic Atrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Geographic Atrophy Therapies and Key Companies

• Pegcetacoplan: Apellis Pharmaceuticals
• Zimura: Iveric bio.
• LBS-008: Belite Bio
• NGM621: NGM Biopharmaceuticals
• PPY988/GT005: Novartis
• OpRegen: CellCure Neurosciences

To know more about Geographic Atrophy treatment, visit @ Geographic Atrophy Medications

Geographic Atrophy Market Drivers

• Increasing prevalence rate
• Geographic Atrophy Emerging novel treatment options
• Patient-friendly Dosage Regimes

Geographic Atrophy Market Barriers

• Failure of Investigational
• Limited knowledge of Geographic Atrophy
• Lack of access to specialists

Scope of the Geographic Atrophy Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Geographic Atrophy Companies: Apellis Pharmaceuticals, Iveric bio., Belite Bio, NGM Biopharmaceuticals, Novartis, CellCure Neurosciences, and others
• Key Geographic Atrophy Therapies: Pegcetacoplan, Zimura, LBS-008, NGM621, PPY988/GT005, OpRegen, and others
• Geographic Atrophy Therapeutic Assessment: Geographic Atrophy current marketed and Geographic Atrophy emerging therapies
• Geographic Atrophy Market Dynamics: Geographic Atrophy market drivers and Geographic Atrophy market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Geographic Atrophy Unmet Needs, KOL’s views, Analyst’s views, Geographic Atrophy Market Access and Reimbursement 

Discover more about therapies set to grab major Geographic Atrophy market share @ Geographic Atrophy market forecast

Table of Contents 

1. Geographic Atrophy Market Report Introduction

2. Executive Summary for Geographic Atrophy

3. SWOT analysis of Geographic Atrophy

4. Geographic Atrophy Patient Share (%) Overview at a Glance

5. Geographic Atrophy Market Overview at a Glance

6. Geographic Atrophy Disease Background and Overview

7. Geographic Atrophy Epidemiology and Patient Population

8. Country-Specific Patient Population of Geographic Atrophy 

9. Geographic Atrophy Current Treatment and Medical Practices

10. Geographic Atrophy Unmet Needs

11. Geographic Atrophy Emerging Therapies

12. Geographic Atrophy Market Outlook

13. Country-Wise Geographic Atrophy Market Analysis (2019–2032)

14. Geographic Atrophy Market Access and Reimbursement of Therapies

15. Geographic Atrophy Market Drivers

16. Geographic Atrophy Market Barriers

17.  Geographic Atrophy Appendix

18. Geographic Atrophy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/